<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00995540</url>
  </required_header>
  <id_info>
    <org_study_id>E-201</org_study_id>
    <nct_id>NCT00995540</nct_id>
  </id_info>
  <brief_title>Tolerability, Safety, and Efficacy Study of INGAP Peptide to Treat Type 1 Diabetes Mellitus in Adults</brief_title>
  <official_title>A Multiple-center, Randomized, Double-blind, Placebo-controlled, Parallel Study to Assess the Tolerability, Safety, and Efficacy of INGAP Peptide Given Subcutaneously as Injections t.i.d. for 12 Weeks in Adult Patients With Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exsulin Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exsulin Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      INGAP Peptide acetate is the active ingredient of INGAP Peptide Solution for Injection. It is&#xD;
      being developed as an antidiabetic agent for the restoration of endogenous insulin secretion&#xD;
      in patients with type 1 diabetes mellitus (T1DM) and in insulin-deficient patients with type&#xD;
      2 diabetes mellitus (T2DM). This clinical study is designed to generate additional data&#xD;
      regarding the appropriate dose and dosing regimen and to evaluate safety and efficacy in&#xD;
      patients with T1DM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In contrast to currently approved therapies that are directed at controlling either the&#xD;
      metabolic abnormalities or tissue complications of diabetes, INGAP Peptide therapy is&#xD;
      intended to restore ß cell mass and islet cell function. INGAP Peptide has been identified as&#xD;
      a substance that induces islet cell regeneration from progenitor cells resident in the&#xD;
      pancreas in a manner that recapitulates islet development during normal embryogenesis.&#xD;
&#xD;
      INGAP Peptide therapy has been evaluated in phase 1 and 2 studies of both T1DM and T2DM&#xD;
      patients (Dungan K, Diab Met Res Rev 2009; 25:558-565). Once daily injections of INGAP&#xD;
      Peptide for 3 months caused a statistically significant increase in C peptide secretion in&#xD;
      T1DM patients, and a trend towards increased C-peptide levels was seen in T2DM patients.&#xD;
      Glycosylated hemoglobin (HbA1c) decreased by -0.6% (p&lt;0.0125) in T2DM patients and by -0.4%&#xD;
      (p&lt;0.06) in T1DM patients.&#xD;
&#xD;
      Given the very short half-life or INGAP Peptide (i.e., &lt;1 hour), the findings of these&#xD;
      earlier phase 2 studies in patients with T1DM and T2DM are very encouraging in that despite&#xD;
      suboptimal exposure to the drug, there was evidence of efficacy. Local injection site&#xD;
      reactions observed in those studies may have been due to relatively large doses of&#xD;
      formulations that were not optimized for tonicity and patient comfort.&#xD;
&#xD;
      This study has been designed such that the dose of INGAP Peptide will be divided across three&#xD;
      daily administrations using a formulation that has been improved with respect to tonicity.&#xD;
      The study will evaluate the safety, tolerability and C-peptide response associated with this&#xD;
      dosing regimen in patients with T1DM.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Preserve clinical supplies&#xD;
  </why_stopped>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Injection tolerability</measure>
    <time_frame>4-8-12-16 weeks</time_frame>
    <description>Local injection site</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-peptide</measure>
    <time_frame>4-8-12-16 weeks</time_frame>
    <description>Maximal C-peptide (Cmax) and C-peptide AUC during mixed meal test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous injection tid for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg INGAP Peptide tid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg INGAP Peptide tid subcutaneous injection for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg INGAP Peptide tid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mg INGAP Peptide tid subcutaneous injection for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INGAP Peptide</intervention_name>
    <description>100 mg INGAP Peptide tid subcutaneous injection for 12 weeks</description>
    <arm_group_label>100 mg INGAP Peptide tid</arm_group_label>
    <other_name>Exsulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INGAP Peptide</intervention_name>
    <description>200 mg INGAP Peptide tid subcutaneous injection for 12 weeks</description>
    <arm_group_label>200 mg INGAP Peptide tid</arm_group_label>
    <other_name>Exsulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tid subcutaneous injection for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients meeting all of the following criteria will be eligible for enrollment in the&#xD;
        study:&#xD;
&#xD;
          -  Male and female patients between the ages of 19 and 60 years old, inclusive, with a&#xD;
             history of T1DM for &gt;2 years and ≤40 years;&#xD;
&#xD;
          -  Receiving multiple daily insulin injections or insulin pump therapy for &gt;2 years;&#xD;
&#xD;
          -  Body mass index (BMI) ≤32 kg/m2;&#xD;
&#xD;
          -  HbA1c ≤7.7%;&#xD;
&#xD;
          -  Fasting C-peptide levels &lt;0.6 ng/mL&#xD;
&#xD;
          -  Willing to sign the study informed consent document;&#xD;
&#xD;
          -  In good general health with no late severe complications or concomitant medical&#xD;
             conditions that would influence the outcome of the trial, at the discretion of the&#xD;
             Investigator and the Sponsor;&#xD;
&#xD;
          -  If treated with angiotensin-converting enzymes/angiotensin II receptor blockers&#xD;
             (ACE/ARB), the doses should be unchanged for a month prior to enrollment; and&#xD;
&#xD;
          -  Females of child bearing potential must have a negative urine pregnancy test on Day 0&#xD;
             prior to dispensing drug and should additionally fulfill one of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Willing to use oral, implantable, transdermal, or injectable contraceptives for&#xD;
                  21 days prior to the first dose and until 28 days after the last dose; or,&#xD;
&#xD;
               -  Willing to use another reliable means of contraception approved by the&#xD;
                  Investigator (intrauterine device, female condom, diaphragm with spermicide,&#xD;
                  cervical cap, use of condom by sexual partner, or a sterile sexual partner) from&#xD;
                  Screening until after the last blood sample (at Week 16).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients meeting any of the following criteria will be excluded from study participation:&#xD;
&#xD;
          -  • Total daily insulin dosage exceeding 1.0 U/kg/day or a change in total daily insulin&#xD;
             dose level of more than 50% (increase or decrease) within the past 3 months;&#xD;
&#xD;
          -  Treatment with any diabetes medication other than insulin;&#xD;
&#xD;
          -  A score of 4 or more restricted responses on the Clarke Hypoglycemia Awareness Survey;&#xD;
&#xD;
          -  Systolic or diastolic blood pressure &gt;180 mmHg or &gt;110 mmHg, respectively;&#xD;
&#xD;
          -  Clinical worsening of retinopathy or neuropathy in the previous 3 months;&#xD;
&#xD;
          -  Clinical worsening of nephropathy in the previous 3 months, or blood urea nitrogen&#xD;
             (BUN) and serum creatinine exceeding 50 mg/dL and 2.0 mg/dL, respectively;&#xD;
&#xD;
          -  History or presence of acute or chronic pancreatitis, including a serum amylase level&#xD;
             &gt;1.5 times the upper limit of normal (ULN) or a serum lipase level &gt;2 times ULN;&#xD;
&#xD;
          -  A history or presence of any illness, disease, or condition that could impact patient&#xD;
             safety or evaluability of drug effect, in the Investigator's opinion;&#xD;
&#xD;
          -  An episode of severe hypoglycemia (change in mental status requiring assistance)&#xD;
             during the previous 30 days;&#xD;
&#xD;
          -  An episode of acute glycemic decompensation with associated hyperosmolar non-ketotic&#xD;
             state or diabetic ketoacidosis during the past 6 months;&#xD;
&#xD;
          -  A serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total&#xD;
             bilirubin level &gt;2 times ULN;&#xD;
&#xD;
          -  Received any investigational product within 30 days of admission into this study or&#xD;
             had any prior or existing exposure to INGAP Peptide or glucagon-like peptides (GLP 1,&#xD;
             GLP 2, or analogs);&#xD;
&#xD;
          -  Concurrent or planned participation in any other clinical study during the conduct of&#xD;
             this study;&#xD;
&#xD;
          -  Positive urine test for cocaine, opiates, amphetamines, or cannabinoids;&#xD;
&#xD;
          -  Inability to fill out and maintain a daily diary during the screening period prior to&#xD;
             dosing; or,&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis&#xD;
             C seropositivity in blood sample taken during screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yogish Kudva, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>George Tsoukas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University - Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>October 13, 2009</study_first_submitted>
  <study_first_submitted_qc>October 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2009</study_first_posted>
  <last_update_submitted>February 11, 2014</last_update_submitted>
  <last_update_submitted_qc>February 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>T1DM</keyword>
  <keyword>Regeneration</keyword>
  <keyword>Islet</keyword>
  <keyword>Beta cell</keyword>
  <keyword>INGAP Peptide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

